In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Connections, collaboration key to executing global trials
Leon Dzivinsky shares his insights on navigating borders, cultures, regulatory issues and other important considerations on worldwide studies.
-
Rare disease clinical trials call for intelligent design
Will Maier and Scott Schliebner offer expert advice on planning and executing clinical studies with the unique needs of rare disease patients in mind.
-
A multifaceted global approach to addressing antimicrobial resistance
Dr. Caroline Forkin, VP Clinical Research Services, considers the best approach to address antimicrobial resistance.
This article is taken from European Biopharmaceutical Review October 2021, pages 70-73. Samedan Ltd
-
The future of clinical trials
Dr. Greg Licholai, Chief Medical Information Officer, discusses key market trends, the future of clinical trials and the acquisition of PRA.
-
The waterfall effect of digital health technology on unifying healthcare and clinical research
Isaac R Rodriguez-Chavez contributes to the DPHARM Autumn 2021 newsletter, discussing the use of digital health to maximise efficiencies in decentralised clinical trials.
-
CROs: Yesterday, today, and tomorrow
ICON's Kent Thoelke discusses today’s key trends for CROs, including the increasing adoption of decentralised clinical trials (DCTs) and the growing use of remote monitoring to collect data.
-
-
Top 10 factors to design and deploy a decentralised clinical trial
Dr. Isaac Rodriguez-Chavez considers the top 10 factors when designing and deploying a decentralised clinical trial.
This article is taken from International Clinical Trials August 2021, pages 8-10. Samedan Ltd.
-
Europe’s emerging biotechs: Challenges, opportunities and funding
John Macdonald, Vice President, Venture & Financial Alliances, examines the European biotech sector – its expertise and opportunities, and potential for growth.
-
Recruiting patients for real-world studies
William Maier, VP Rare Diseases, Drug Development Sciences, considers the benefits of digital recruitment campaigns for recruiting patients for real-world studies.
